Wegovy cover art

Wegovy

Wegovy

By: Quiet. Please
Listen for free

About this listen

 This series on Wegovy provides an in-depth look into the popular weight loss medication. The first episode introduces Wegovy, explaining its mechanism, clinical trials, and patient eligibility. The second episode delves into the benefits and potential risks, including effectiveness, side effects, and comparisons with other treatments. The final episode covers practical considerations such as usage, lifestyle integration, cost, and future developments. This series offers a comprehensive understanding for anyone considering Wegovy as a weight management solution.2024 Quiet. Please Hygiene & Healthy Living Physical Illness & Disease
activate_mytile_page_redirect_t1
Episodes
  • Wegovy Breakthrough: New Study Shows Zepbound Leads in Weight Loss Effectiveness and Expanding Healthcare Coverage

    Wegovy Breakthrough: New Study Shows Zepbound Leads in Weight Loss Effectiveness and Expanding Healthcare Coverage
    May 12 2025
    # Latest Developments in the World of Wegovy: Breaking News and Market Shifts

    In this information-packed episode, host Alexandra Reeves delivers crucial updates on Wegovy and the evolving weight loss medication landscape. Learn about the groundbreaking head-to-head study published in the New England Journal of Medicine comparing Wegovy to Zepbound, with surprising results showing Zepbound users lost approximately 20.2% of body weight compared to Wegovy's 13.7%.

    The episode covers important insurance developments beginning January 2025, with expanded coverage for Wegovy following FDA approval for cardiovascular risk reduction. Discover how these medications impact not just weight but also blood pressure, diabetes metrics, and cholesterol levels.

    Alexandra discusses Novo Nordisk's unexpected FDA submission withdrawal for heart failure treatment approval, political shifts affecting Medicare coverage, and exciting research suggesting semaglutide may help treat liver disease. Get insights on supply chain improvements and what these developments mean for patients seeking weight management solutions.

    Perfect for healthcare professionals, those considering weight loss medications, or anyone interested in the latest medical breakthroughs, this episode provides comprehensive coverage of Wegovy's evolving role in modern medicine.
    Show More Show Less
    5 mins
  • Novo Nordisk Advances Wegovy with First Oral GLP-1 Weight Loss Treatment Targeting Obesity Management

    Novo Nordisk Advances Wegovy with First Oral GLP-1 Weight Loss Treatment Targeting Obesity Management
    May 10 2025
    # Podcast Episode: Novo Nordisk's Breakthrough - First Oral GLP-1 Weight Loss Treatment on the Horizon

    In this episode, we dive into Novo Nordisk's groundbreaking advancement with Wegovy, as they make significant progress toward developing the first-ever oral GLP-1 weight loss medication. The FDA has recently accepted Novo Nordisk's New Drug Application for an oral formulation of their popular weight loss treatment, potentially revolutionizing obesity management.

    We explore how this once-daily pill could transform treatment options for patients currently using injectable Wegovy, with clinical trials showing impressive 13.6% average weight loss. The episode also covers Wegovy's expanded medical applications, including its historic FDA approval for reducing cardiovascular risks, positive news about resolved supply shortages, and ongoing research into additional benefits for liver disease and dementia prevention.

    Perfect for healthcare professionals, patients considering weight loss treatments, or anyone interested in pharmaceutical innovations, this episode provides comprehensive insights into the evolving landscape of obesity management and what this potential game-changing oral medication could mean for millions of people worldwide.

    #WeightLossBreakthrough #OralGLP1 #ObesityTreatment #NovoNordisk #Wegovy #PharmaceuticalInnovation #WeightManagement
    Show More Show Less
    5 mins
  • Wegovy Oral Medication Breakthrough: FDA Review Signals New Era in Weight Loss Treatment and Obesity Management

    Wegovy Oral Medication Breakthrough: FDA Review Signals New Era in Weight Loss Treatment and Obesity Management
    May 3 2025
    # Wegovy: The Latest Developments in Weight Loss Medication - Breaking News and Market Shifts

    Discover the groundbreaking developments in the weight loss medication landscape as host Alexandra Reeves dives deep into Novo Nordisk's Wegovy. This episode unpacks the FDA's recent action date for an innovative oral formulation of Wegovy that could revolutionize obesity treatment, potentially becoming the first oral GLP-1 drug for chronic weight management.

    Learn about the major market shift as CVS Caremark names Wegovy its preferred GLP-1 treatment for obesity, effectively reshaping competition in the pharmaceutical industry. The podcast explores how this decision impacted Eli Lilly's stock and what it means for patients currently using competing medications.

    Alexandra also examines Novo Nordisk's strategic moves to improve medication accessibility, including their launch of NovoCare Pharmacy offering reduced costs for self-paying patients and expanded telehealth collaborations. Get insights into the medication's potential side effects, approval history, and the fascinating origin story behind Novo Nordisk itself.

    Perfect for healthcare professionals, individuals managing weight issues, or anyone interested in pharmaceutical innovations, this episode provides crucial context for understanding how these developments will shape the future of obesity treatment.
    Show More Show Less
    6 mins

What listeners say about Wegovy

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.